#Personal Breast Scanner India

[iscanbreast]

iSCANBREAST is a product for women designed for their health and wellbeing. The product helps women to self-examine their breasts & understand the basic structure by showing the inner view of their breasts. iSCANBREAST is equipped with cutting-edge LED light technology that helps to see through breast's tissue & view the internal structure of the breast to detect any potential abnormalities. For more information contact us 80-84, Melange Towers, Patrika Nagar, Madhapur, Telangana 500081, tel:18001020576, listen@azistaindustries.com, www.iscanbreast.com.

[healthcareandwellness-blog]

Market Introduction

Tissue diagnostic is considered as the medical test that is mainly performed by the interventional radiologist, surgeon or an interventional cardiologist to determine presence of any disease or an extent of any disease. The procedure includes extraction of sample cells from the body and examining them with the help of microscope or can be analyzed chemically.

Market Dynamics

Increasing number cancer patients across the globe has resulted in the rise in demand for tissue diagnostics. Common forms of cancer that have proven to be fatal include lung cancer, breast cancer and liver cancer (pancreatitis). According to Insights and Reports, the U.S recorded more than 15 million cancer survivors in 2016 and it is expected that adequate diagnostic methods would increase the number of cancer survivors in the coming years as well. High healthcare spending in the country is another key factor boosting the demand for tissue diagnostics. According to the National Health Expenditure Accounts (NHEA), the healthcare spending in the U.S. reached US$ 3.3 trillion in 2016, which also equals US$ 10,348 per person. Further, adequate public healthcare system in the country is also a key factor resulting in the high growth of the tissue diagnostics market in the country.

 Request for a sample copy of this report @

https://www.insightsandreports.com/request-sample/67

 However, low public spending on healthcare facilities in the developing economies such as India, due to lack of proper infrastructural development is one of the key factors barring the growth of the tissue diagnostics market. According to Insights and Reports, the government of India spends roughly 1.4% of the GDP on healthcare. Further, the government also does not provide adequate primary and secondary medical care as a result of which, more than 75% of these services are provided by the hospitals plying in the private sector. Due to this factor, the rural population in India is devoid of adequate healthcare services, which in turn is hampering the market growth of tissue diagnostics.

 Market Segmentation and Analysis

The global tissue diagnostic market has been segmented on the basis of product type, technology and end-user. On the basis of product type the market has been bifurcated into consumables and instruments. Consumables are further segmented into Kits Antibodies, Probes, and Reagents among others. On the other hand instruments have further segmented into scanners, slide staining system, tissue processing system among others. Consumables segment dominated the market owing to the rising in advancements in the technology over the years On the basis of technology the market has been segmented into Immunohistochemistry, In situ hybridization, digital pathology and special staining. Immunohistochemistry technology dominated the market owing to the rising adoption as well as an efficient process to detect any antigen within the tissue. Such techniques are sensitive and provide accurate results for better understanding of the diseases. By end-use the market has been segmented into hospitals, ambulatory surgical centers, research laboratories and diagnostic centers.

 For more information about this report @ https://www.insightsandreports.com/industry-reports/tissue-diagnostic-market

 Geographical Outlook

In terms of region the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa and Latin America. North America and Europe captured a significant market share owing to the rising awareness towards proper health and wellness among the population. High spending on healthcare in U.K. is one of the key factors driving the demand for tissue diagnostics market in the country. Healthcare spending in U.K. amounted to roughly US$ 260.19 Bn in 2017, with government spending accounting for more than 80% of the total healthcare spending. In addition, long term healthcare spending in the U.K. was recorded at US$ 51.32 Bn in 2017. According to Insights and Reports, U.K. saw more than 367,820 new cases of cancer in 2016. These factors are highly supporting the growth of the tissue diagnostic market in the country.

 Competitive Landscape

Some of the major key players of the global tissue diagnostic market are Roche, Danaher, Thermo Fisher Scientific, Abott Laboratories, Agilent Technologies, Merck KGaA, Sakura Finetek Japan, Abcam, Biogenex Qiagen among others.

  About Us:

Insights and Reports is a research and consulting group assisting the clients with 360-degree insights with real time qualitative and quantitative information. The Insights and Reports team is valued for continuous client-oriented services. Our data scientists monitor the markets pertaining to their expertise on a daily basis with the help of 150+ analysts to back them with accurate market studies.

 Contact Us:

Mr.Saby

Insights And Reports,

2201 Cooperative Way #600,

Herndon, VA 20171, USA.

Tel: +1 703 574 4447

Email:sales@insightsandreports.com

[healthcare-market]

Microarray Scanners Market Report Analysis With Industry Share

Microarray Scanners Market: Introduction

According to the report, the global microarray scanners market was valued at US$ 700 Mn in 2019 and is projected to expand at a CAGR of ~7% from 2020 to 2030. Emergence and adoption of technologically advanced instruments in life science, rise in demand for preventive healthcare, well-established healthcare facilities, rapidly increasing geriatric population, and high per capita healthcare expenditure are anticipated to drive the global microarray scanners market from 2020 to 2030. North America is expected to account for significant share of the global microarray scanners market during the forecast period. The growth of the market in the region can be attributed to well-established healthcare and life sciences industries, early adoption of technologically advanced products, high awareness about various infectious as well as chronic diseases, and high per capita healthcare expenditure.

The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031, due to the expansion of the healthcare sector in countries such as China, Japan, and India. Moreover, increase in drug research & development in countries such as Japan, India, and China is projected to propel the market in the region during the forecast period.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45156

Rise in Awareness, Acceptance of Personalized Medicine, Companion Diagnostics to Propel Market

The demand for personalized medicine is increasing at a significant rate. Personalized medicine is defined as a practice of customization of an individual’s requirement using genetic profiling. Inclination toward personalized medicines can be ascribed to the efficiency and target-specific nature of medicines with better patient outcomes. According to a study published in the World Academy of Sciences Journal 2019, protein microarrays are paving the way for personalized medicine. Personalized medicine aims to stratify patients as per type of the disease, treatment response, evaluated prognosis, and its risk factors. Microarrays are being tried to develop personalized medicine for various disease types, including cell renal carcinoma, breast & ovarian cancers, and pulmonary diseases.

Additionally, targeted therapies have minimal or no side effects compared to conventional therapies. Significant sophistication in genomics research and biomarkers has encouraged several pharmaceutical companies to shift focus toward the development of novel targeted therapies. This accelerated adoption of companion diagnostics has led to a gradual decline of the traditional model.

Request for Analysis of COVID19 Impact on Microarray Scanners Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=45156

Fluorescence Microarray Scanners to Dominate Market

In terms of product type, the global microarray scanners market has been classified into fluorescence microarray scanners, charge-coupled devices microarray scanners, colorimetric microarray scanners, and others. The fluorescence microarray scanners segment is expected to dominate the global microarray scanners market by 2030. Fluorescence microarray scanners are highly common and widely utilized microarray detection devices. This is expected to drive the segment during the forecast period.

Gene Expression to be Highly Attractive Application

Based on application, the global microarray scanners market has been categorized into gene expression, drug discovery, and others. The gene expression segment is projected to dominate the global microarray scanners market during the forecast period. Application of gene expression for profiling for diseases, such as cardiovascular diseases including endothelial dysfunction, myocardial infarction, heart failure, cardiac hypertrophy, and atherosclerosis, is expected to drive the segment during the forecast period.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=45156

Diagnostic Laboratories to Account for Major Market Share

In terms of end user, the global microarray scanners market has been divided into hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, and academic & research institutes. The diagnostic laboratories segment is anticipated to account for a significant share of the global microarray scanners market by 2030. Diagnostic laboratories is expected to be a highly lucrative segment due to availability of facilities in diagnostics labs.

Buy now Microarray Scanners Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=45156&ltype=S

Competition Landscape in Microarray Scanners Market

The report provides profiles of leading players operating in the global microarray scanners market. These include Thermo Fisher Scientific, Agilent Technologies, Illumina, Inc., PerkinElmer Inc., F. Hoffmann-La Roche Ltd., GE Healthcare (General Electric Company), Molecular Devices, LLC (Danaher Corporation), Innopsys Inc., and Berthold Technologies GmbH & Co. KG.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/availability-of-sizeable-number-of-lightweight-devices-especially-for-use-by-the-elderly-substantiates-impressive-demand-in-oxygen-conserving-devices-market-continued-rd-to-spur-growth-says-tmr-301307841.html

https://www.prnewswire.com/news-releases/rising-number-of-osteoporosis-cases-boosts-demand-avenues-in-viscosupplementation-market-says-transparency-market-research-301312591.html

https://www.prnewswire.com/news-releases/rising-diabetic-patients-pool-prompts-high-demand-for-smart-insulin-pens-market-estimated-to-be-valued-at-us-70-4-mn-by-2027-end-tmr-301316368.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

[medi-healthcare]

Top 7 Pulmonology Hospitals in India

Source:- https://www.rateyourtreatment.com/General/single-Blog.aspx/top-7-pulmonology-hospitals-in-india

Check out top-rated pulmonology hospitals in India: -

Apollo Hospital

Location: Greams Road, Chennai

Accreditation: JCI

One of the renowned healthcare facilities, Apollo Hospital, has established its position in the healthcare industry by serving patients with the best treatment and care. It is recognized among the top pulmonology centers across India. The center of respiratory medicines serves top-quality treatment with a well-qualified team of chest physicians and pulmonologists.

Indraprastha Apollo Hospital

Location: Sarita Vihar, New Delhi

Accreditation: JCI

The Indraprastha Apollo Hospital, situated in Delhi, has an advanced, fully equipped respiratory, sleep and critical care department. With world-class infrastructure, it houses state-of-the-art facilities and a hi-tech environment to treat patients. A team of highly qualified doctors manages its medical Intensive Care Unit, Bronchoscopy unit, two pulmonary functional laboratories, and Sleep Lab.

Max Super Speciality Hospital

Location: Saket, Delhi

Accreditation: NABH & JCI

Max Healthcare offers multidisciplinary treatment, including bronchoscopy for patients who have respiratory ailments, lung cancer, COPD, sleep problems, and Cystic Fibrosis. It renders top-notch treatment and the finest quality care to its patients. With a fully equipped pulmonary function laboratory and advanced infrastructure, it comprises a team of experts who also provide ancillary services, including respiratory care and nutrition. Emergency and pharmaceutical services are available round the clock.

Nanavati Hospital

Location: Vile Parle West, Mumbai

Accreditation: NABH

Spread across 10,000 sq. ft., Nanavati Hospital is among the most well-known centers of healthcare excellence in India. The comprehensive unit of pulmonology comprises state-of-art departments, ultra-modern systems, with modern medicine. This healthcare facility has a committed team of chest physicians, interventional pulmonologists, technicians, and staff to treat various pulmonary illnesses. From hypertension, respiratory diseases, asthma to sleep disorders, allergic diseases, tuberculosis, etc., the hospital provides the best of its services. Moreover, it uses 3 Tesla 32 channel wide-bore MRI scanners for chest and breast imaging to diagnose lung disorders.

Fortis Hospital

Location: Bannerghatta Road, Bangalore

Accreditation: NABH

Fortis is yet again one of the esteemed healthcare facilities in the country. The Pulmonology department provides both flexible and rigid bronchoscopy services. Equipped with the highest technology and top-quality facilities, the department utilizes all the latest and modern tools to treat respiratory illnesses. The team of skilled pulmonologists works hand-in-hand with the experts of other specialties to deliver personalized and effective care.

BLK Super Speciality Hospital

Location: Delhi

Accreditation: NABH

Situated in Delhi, BLK Super Speciality Hospital embraces a dedicated department of respiratory medicine dealing with an entire range of respiratory conditions. With best-in-class technology and expert professionals, the healthcare facility ensures world-class treatment for its patients. It treats a range of respiratory problems including, asthma and allergic diseases, chronic obstructive pulmonary disease (COPD), lung infections like tuberculosis, interstitial lung diseases, pulmonary hypertension. The Centre offers quality diagnostic, therapeutic, and medical interventions as part of its advanced care and treatment plan.

Columbia Asia Hospital

Location: Hebbal, Bangalore

Accreditation: NABH

Columbia Asia Hospital incorporates one of the finest pulmonary centers in India. It is specially designed for patients suffering from clinical pulmonology disorders. The department is structured with digitized systems and the latest technological innovations to provide a complete range of medical assistance. The division offers management of acute and chronic lung diseases by a team of highly proficient and experienced physicians.

Also, do not forget to read their reviews on RateYourTreatment.com!

[rdagade]

Asia Pacific MRI (Magnetic Resonance Imaging) Market

Asia Pacific MRI (Magnetic Resonance Imaging) Market is expected to reach USD XX Billion by 2027 from USD XX Billion in 2019 at a CAGR of XX% (Detailed analysis of the market CAGR is provided in the report).

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.

To know about the Research Methodology:-Request Free Sample Report

An MRI also was known as magnetic resonance imaging scan is a special radiology technique that uses magnetism, radio waves, and a computer to produce images of different body structures. The image as well as the resolution produced by MRI is quite detailed and can even detect tiny changes of structures occurring within the body. For certain procedures, contrast agents, such as gadolinium, are also used to enhance the accuracy of the images.

An MRI scan is used as an extremely accurate method of disease detection present throughout the body and are often able to provide sufficient information confirming a patient's diagnosis. Especially in the head, any form of trauma to the brain such as bleeding or swelling are detected using MRI. Other abnormalities include brain aneurysms, stroke, tumours of the brain, as well as tumours or inflammation of the spine along with other neurological diseases have resulted in brain and neurological MRI holding a significant share of the overall Asia Pacific MRI (Magnetic Resonance Imaging) Market.

Neurosurgeons use MRI scan not only for defining brain anatomy but also for evaluating the reliability of the spinal cord after trauma. An MRI scan can further help evaluate the structure of the heart and aorta for detecting aneurysms or tears with the cardiac segment forming another major application area for the MRI market in the Asia Pacific.

It provides valuable facts on glands and organs within the abdomen, and precise information about the structure of the joints, soft tissues, or bones present in the body. Often, surgeries are more accurately directed after knowing the results of an MRI scan. Metallic chips, materials, surgical clips, or any foreign material such as artificial joints or prosthetic devices may significantly distort the images obtained by the MRI scanner forming a key restraint for the market.

The Asia Pacific is one of the major markets for MRI globally where China and India among others are the two major regions profiled under Asia Pacific MRI (Magnetic Resonance Imaging) Market report. Changing healthcare infrastructure along with the probabilities of achieving a desired patient information are certain key contributing factors to boost the market for Asia Pacific MRI (Magnetic Resonance Imaging) Market. Asia Pacific MRI (Magnetic Resonance Imaging) Market, Key Highlights:

• Asia Pacific MRI (Magnetic Resonance Imaging) Market size analysis and forecast • Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the Asia Pacific MRI market • Asia Pacific MRI (Magnetic Resonance Imaging) Market segmentation on the basis of application, architecture, field strength, and geography • Asia Pacific MRI (Magnetic Resonance Imaging) Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of a study • Asia Pacific MRI (Magnetic Resonance Imaging) Market analysis and forecast for major countries have been provided. • Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies • Competitive landscape of the key players operating in the Asia Pacific MRI (Magnetic Resonance Imaging) Market including competitive developments, investments, and strategic expansion Key players of the Asia Pacific MRI (Magnetic Resonance Imaging) Market :

• Neusoft Medical • Ningbo Xingaoyi Magnetism Co. Ltd • GE Healthcare • Philips Healthcare • Siemens Healthcare • ANKE Medical • Fujifilm Holdings • Shimadzu Corporation • Toshiba Medical Systems Corporation • Carestream Health • Hitachi Medical Corporation • Esaote • Green Medical Co., LTD • Mitsubishi Research Institute, Inc. • Fair Medical Co Ltd. Japan • JAPAN CARE CO., LTD • Sanrad Medical Systems • Medirays Corporation • MRI Services • Edge Medical Solutions • Blue Star • Alpenglow Australia • I-MED Radiology Network • MRI e-cycle solutions • Voyager Imaging • MRI Now • Resonance Health • Magnetica

For more information visit@ https://www.maximizemarketresearch.com/market-report/asia-pacific-mri-magnetic-resonance-imaging-market/10225/

The Scope of the Asia Pacific MRI (Magnetic Resonance Imaging) Market: Inquire before buying

The research report segments Asia Pacific MRI market based on application, architecture, field strength, and geography. Asia Pacific MRI (Magnetic Resonance Imaging) Market,by Application:

• Spine and musculoskeletal MRI • Brain and neurological MRI • Vascular MRI • Pelvic and Abdominal MRI • Breast MRI • Cardiac MRI Asia Pacific MRI (Magnetic Resonance Imaging) Market, by Architecture:

• Open MRI Systems • Closed MRI Systems • Standard Bore • Wide Bore Asia Pacific MRI (Magnetic Resonance Imaging) Market, by Field Strength:

• Low-to-mid Field • High-field • 1.5T • 3T • Very-high Field Asia Pacific MRI (Magnetic Resonance Imaging) Market, By Geography:

• Asia Pacific • China • Japan • India • South Korea • Australia Asia Pacific MRI (Magnetic Resonance Imaging) Market, Geographic Analysis:

• Breakdown of China MRI market • Breakdown of Japan MRI market • Breakdown of India MRI market • Breakdown of South Korea MRI market • Breakdown of Australia MRI market Available Customizations:

Maximize Market Research offers customizations of reports according to the specific requirement of our clients.

This report submitted by Maximize market Research Company

Customization of the report:

Maximize MarketResearch provides free personalized of reports as per your demand.This reportcan be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

[adwaitcoherent]

By 2026, PET-CT Scanner Device Market To Surpass US$ 3 Billion - Coherent Market Insights

PET-CT Scanner Device Market To exhibit a CAGR of 5.1% over the forecast period (2018 - 2026).

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2169

Description:

A positron emission tomography (PET) - computed tomography (CT) scan reveals information about both the structure and function of cells and tissues in the body during a single imaging session. In recent times, majority of PET scans are performed on instruments that are combined with PET and CT scanners. The combined PET-CT scans provide images that identify the anatomic location of abnormal metabolic activity within the body. The combined scans have been shown to provide more accurate diagnoses than the two scans performed separately.

 The diagnosis of various diseases such as cancer, heart diseases, and certain brain disorders require the use of both PET and CT scans. PET scanners measure metabolic activity, whereas CT scanners highlight anatomical features. The risk to poor superimposition of separate imaging is reduced and the hybrid PET-CT process lessens burden on the patient by simplifying the scanning process. The use of PET-CT scanner hybrids combine the strengths of two well-established imaging modalities and helps in accurate diagnosis, localizing, and monitoring of the disease. Moreover, PET-CT scanners can record the images in extremely short time (less than a minute).

 The global PET-CT scanner device market size was valued at US$ 1.9 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026).

 Global PET-CT Scanner Device Market Share (%) Analysis, By Application, 2017

PET-CT Scanner Device | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2018)

 Increasing prevalence of chronic diseases and rising geriatric population is expected to drive the PET-CT scanner device market revenue

 Rising prevalence of infectious and chronic diseases such as cancer and heart disease across the globe and increasing demand for effective diagnostic systems is expected to drive the PET-CT scanner market size. According to the National Centre for Health Statistics, 2011, heart disease is the leading cause of death in the U.S., killing over 600,000 people each year.

 According to the International Agency for Research on Cancer (IARC), in 2012, an estimated 14.1 million new cancer cases were reported, globally. Among these, the most common form of cancer was lung cancer (13%), breast cancer (11.9%), and colorectal cancer (9.7%). According to the Centers for Disease Control and Prevention (CDC), February 2018 data, around 22,000 men and 9,000 women suffer from liver cancer, and around 16,000 men and 8,000 women die due to liver cancer, every year in the U.S.

 Moreover, rising cases of brain illness such as Alzheimer’s and traumatic brain injury is also contributing to market growth. For instance, according to the Alzheimer’s Association, in 2017, over 5 million people were estimated to be suffering from Alzheimer’s disease, which was also reported to be the sixth-leading cause of death in the U.S.

 PET-CT Scanner Device Market - Restraints

 PET-CT scan test results of diabetic patients or patients who consumed any food few hours prior to the examination could be adversely affected, owing to altered blood sugar or blood insulin levels. A person who is very obese may not fit into the opening of a conventional PET-CT unit. Motion artifacts could also be a major problem with PET-CT imaging when compared to the standard PET. Moreover, this scan is not recommended for all patients including pregnant women due to harmful radiation causing side effects to the body. All these factors can negatively impact the PET-CT scanner device market growth.

 PET-CT Scanner Device Market - Regional Insights

 On the basis of region, the global PET-CT scanner device market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global PET-CT scanner device market, owing to rising number of traumatic brain injury cases in the U.S. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2013, around 282,000 people were diagnosed with brain injury and around 50,000 people died due to traumatic brain injury in the U.S. It is estimated to be a major cause of disability and death in the U.S.

 Europe is also expected to show significant growth in the PET-CT scanner device market, owing to huge number of installed devices and presence of major industry players such as Koninklijke Philips N.V., Siemens AG, and others in the region contributing major revenue share to the market. According to the European Association of Nuclear Medicine (EANM) Annual Congress held in France, in 2012, there were 577 providers of PET and/or PET/CT in Western Europe, and PET/CT accounted for 92% of the installed systems.

 Moreover, the installed base of PET-CT continues to shift from larger institutions into settings such as general hospitals and private practice. Increasing government funding is also a major factor for the technology adoption. For instance, in England, as of August 2015, PET-CT is funded centrally by the National Health Service (NHS) England.

 Global PET-CT Scanner Device Market Value (US$ Mn) & Y-o-Y Growth (%)

         PET-CT Scanner Device  | Coherent Market Insights

  Source: Coherent Market Insights Analysis (2018)

 PET-CT Scanner Device Market - Competitive Landscape

 Key players operating in the global PET-CT scanner device market include General Electric Co., Hitachi, Ltd., Mediso Ltd., Koninklijke Philips N.V., PerkinElmer, Inc., Positron Corporation, Siemens AG, Shimadzu Corporation, Toshiba Corporation, and Yangzhou Kindsway Biotech Co. Ltd. Manufacturers are continually bringing in new PET/CT design. New technology enables more precise measurements of metabolic processes and data quantification, including assessment of cancerous tissue, neurologic disease, and cardiac blood flow (perfusion).

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

 Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2169

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave.  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[vsplusonline]

Cancer awareness umbrellas from Sri Ramakrishna Institute of Oncology and Research

New Post has been published on https://apzweb.com/cancer-awareness-umbrellas-from-sri-ramakrishna-institute-of-oncology-and-research/

Cancer awareness umbrellas from Sri Ramakrishna Institute of Oncology and Research

An umbrella that bears QR codes on cancer awareness is the latest initiative from Dr. P Guhan, director of Sri Ramakrishna Institute of Oncology and Research. “Umbrellas need not necessarily protect you from rain or shine, it can also save your life by making you aware of cancer,” he says. The awareness campaign gave away over 100 free umbrellas to NGOs and students.“We have done several online campaigns using apps, e-books, animated videos, and websites. Now, we have something unique that is offline. But, this will eventually direct people to the online space where we have consolidated information on all types of cancers.”

Each panel of the umbrella has images of colour ribbons accompanied by a QR code. For example, the code next to the pink ribbon image leads to information on breast cancer, its symptoms, and diagnosis. It also informs about the relevant apps, online videos and other resources. There are specific codes for cancer of the lungs, head and neck, prostrate glands, and so on. Anyone with an android phone has to simply scan with a QR code scanner to access the data. “NGOs can display the umbrella at their meetings to get the attention of the public that in turn can scan and learn all about cancer. It serves our purpose of reaching out in a big way.”

Dr. Guhan admits that there is still great fear associated with cancer. “People are hesitant to approach medical help. We have to constantly remind them that cancer is curable if detected early. More than 50 per cent of cancer cases in India are detected in advanced stage III or stage IV levels. In western countries more than 80 per cent are detected in the early stages. Unfortunately, there is still not much change in this percentage.”

People still seek medical help when the disease has already advanced, he says. “There is so much misinformation related to the side affects of chemotherapy. Many think that radiation leads to mouth ulcers, and that it affects skin colour. They try alternative therapies to avoid any side effects. When they finally come to us when everything fails, it is often at an incurable stage. Early diagnosis ensures cure is the message that needs to reach out.”

Dr. Guhan of Sri Ramakrishna Hospital has launched umbrellas with QR codes to spread awareness on all types of cancer   | Photo Credit: M. Periasamy

The videos and websites also highlight stories of cancer survivors. “Most men and women postpone diagnosis citing other commitments. A missed or neglected diagnosis can have serious consequences. When they come for treatment at an advanced stage, sometimes it is too late. Cancer cure becomes a reality only when detected early,” he reiterates.

For women, breast cancer is the most commonly diagnosed. Recently, they launched specially designed mobile phone covers with a pink logo accompanied by a QR code. On scanning, it redirects users to cancer survivor stories, apps, ebooks and films on breast cancer “There is a two per cent increase, especially among the younger women group of 30 to 40 years. Women above 40 should go for an annual pap smear and mammogram to rule out cervical cancer and breast cancer respectively. A routine annual screening helps in early detection and the treatment may not require radiation or chemotherapy. But in most cases, this is not happening,” says Dr. Guhan.

Watch out

For unusual lumps anywhere in the body

Unexplained fever for more than two weeks

Hoarseness in voice that refuses to settle down

Unexplained weight loss

Sudden increase in size of a mole or lump

Unusual bleeding or discharge

Difficulty in swallowing

Changes in bowel and bladder habits

Sometimes the symptoms may not be cancerous but one has to rule that out by taking medical help

To know more, call: 0422-4389797 or 94428-44775 (open on all days (except Sundays) between 9.00 am to 6.00 pm)

Even the educated have an emotional and psychological fear of cancer. “They have to overcome this. It’s a social responsibility to spread awareness. We are seeing an increase in the number of breast cancer cases, lung, head and neck cancers too. A cancer diagnosis doesn’t mean the end of life. We have so many success stories of cancer survivors who are sports persons, doctors, engineers and others like us leading a normal life.” To follow a healthy lifestyle, one should avoid alcohol and tobacco. And, consume freshly cooked food and avoid foods with preservatives. A moderate exercise regimen and annual cancer screening is important.

Mobile phone covers with QR codes on cancer awareness   | Photo Credit: M. Periasamy

The need to spread awareness about cancer is especially urgent at the school and college level, says the doctor. “Teens have easy access to alcohol and tobacco. Once they develop a liking at an early stage in life, it usually leads to addiction. They become long-term tobacco users. They must know how it affects their health. All the information they need is uploaded. We have animated videos and feel good stories of breast cancer survivors that can be a motivating factor for someone diagnosed with breast cancer.”

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Source link

[priyankaganguly-blog]

PET-CT Scanner Device Market – Qualitative Survey On Trends & Future Scope 2028

“PET-CT Scanner Device Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028” report is examined & issued by “TMR Research”. The report includes latest methodologies, market trends, geographic statistics, market participants, qualitative and quantitative analysis of the market.

Global PET-CT Scanner Device Market: Overview

Positron emission tomography - computed tomography (PET/CT) is a notable technological advancement in multimodal imaging by identifying changes in body at cellular level. PET/CT scanner device combines the measurement of metabolic activity and anatomical features. The integrated imaging combines the strengths of PET and CT and hence shows promise in accurately diagnosing, localizing, and monitoring for a range of diseases. PET/CT scanner device holds vast promise in diagnosing cancer, heart disease and certain brain disorders. In particular, the imaging technology holds great potential in clinical oncology, especially for the staging of solid malignancies needed in colon and lung cancer. Having said that, PET/CT scanner device is still a new application in clinical practice. Owing to its excellent standardization and precision, the imaging is being preferred in clinical trials for improving the outcomes.

Global PET-CT Scanner Device Market: Notable Developments

Some of the recent developments that may influence the contours of the PET-CT scanner device market in a big way are:

Hospitals in developed nations are displaying marked revenue generating potential by showing propensity for advanced oncology services for their patients. To this end they are entering into collaboration with medical technology companies.

Get Brochure of the Report @

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5004

Royal Darwin Hospital (RDH), a prominent hospital in Australia, has in March 2019 entered into a partnership with Siemens Healthineers where the former will have deploy advanced PET CT scanner devices. The healthcare institution intends to use the modality for rapid scanning of medical conditions, using only lower doses of radiation and personalized scans. This also eliminates the need for bed-based imaging that were carried under traditional PET.

Governments in numerous developing countries have become actively interested in assessing and meeting the needs of PET-CT scanner devices in hospitals.

One such measure has been noted recently in India, where the state government of one of its states has been asked by law making agency to submit an assessment of the requirement of PET-CT scanner device in all district headquarters hospitals.

Radiology groups in developing regions are showing a marked inclination of expanding their diagnostic capability by adding PET-CT. One such initiative has been notices in South Africa, where a radiology group in Eastern Cape Province, Africa, has deployed a scanner device in its cancer care center. With this, oncology patients will benefit immensely as now they would not need to seek services outside the province.

Some of the prominent players in the global PET-CT scanner device market are Mediso Ltd., PerkinElmer, Inc., Shimadzu Corporation, Hitachi, Ltd., General Electric Co., and Toshiba Corporation.

Global PET-CT Scanner Device Market: Key Growth Dynamics

Advances being witnessed in Oncological Clinical Practice paves way for New Frontiers

The need for overcoming the limitations of PET and CT in oncology imaging in developing and developed regions is a key factor driving the demand for PET-CT scanner devices. One of the objectives of oncology is to get precise anatomical imaging combined with advanced molecular techniques. The rising demand for a cost-effective non-invasive technique for the staging of cancer is also catalyzing the prospects of the global PET-CT scanner device market.

Request TOC for Detailed Facts & Numbers @

https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5004

PET-CT scanner device are fast gaining traction in multiple areas such as diagnosis, staging, monitoring of cancer management, and radiotherapeutic planning.

Ceaseless Technological Advances create New Avenues

Technology advances have resulted in imaging with better accuracy, performance, and reproducibility, thereby catalyzing the prospects of the global PET-CT scanner device market. Functionalities in focus pertain to resolution and contrast, time-of-flight acquisition, and field-of-view imaging. Further, increasing inclination of healthcare providers toward value-based personalized care is a notable trend boosting the market.

Prevalence of Cancer and Chronic Diseases propelling Demand

In various parts of the globe, the increasing incidence of cancer, especially of lung, breast, and colon is a notable trend boosting the market. PET-CT scanner devices are also witnessing increasing potential in monitoring cardiac conditions. The growing prevalence of cardiovascular diseases is a significant factor fueling the prospects.

Global PET-CT Scanner Device Market: Regional Outlook

On the regional front, developing regions are witnessing rising potential in the global PET-CT scanner device market. In particular, Asia Pacific may show an exceptional potential and may gain shares in the coming years. The growth in the regional market is fueled by rapidly rising elderly populations who need diagnostic and radiology services. Moreover, substantial investments being made by governments in the key economies of the region for modernizing healthcare infrastructures in recent years has been imparting large impetus to the demand for PET-CT scanner device in the coming years. Meanwhile, North America is expected to rise at an attractive pace during the assessment period of 2018–2028.

Comprehensive Overview on Future Aspect of Report @

https://www.tmrresearch.com/petct-scanner-device-market

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

[bangaloreaviation]

This is the third in a three part article of my trip from London to Bangalore.

After getting off my flight from London, I had a horrible headache courtesy my disturbed sleep on the flight. Our plane seemed to have parked at almost the last gate at the terminal and the transfer security was on the other end of the terminal.

(Read our review of Etihad’s A380 here.)

After a very long walk, I reached the transfer security hall, where there was only one x-ray and one body scanning line open. The line was being run by a super rude Filipino guy who was going out of his way to be rude to every passenger who came through the scanner.

Aside from the rude security assistant, one scanner for an entire A380 load of people (assuming ours was the only flight being transferred at that time) is definitely not enough especially with the tight connections Etihad sells. Fortunately since I was one of the first to reach the security check I was through in about five minutes but as I was leaving, the line had grown massively.

The transfer security exits into the duty free area, from there I proceeded to the connecting gate which was half way back in the direction I had just come.

Boarding

Since it was nearing the boarding time printed on the boarding card, I skipped the lounge and headed straight to the gate. I reached the gate about five minutes after the printed boarding time and boarding had not yet begun. After waiting for another 20 minutes, the gate agents finally started calling boarding – a full 25 minutes after the printed boarding time. Nothing annoys me more than an airline forcing everyone to come to the gate early and then not start boarding, if you print a time on the boarding pass then stick to it.

When the agents called boarding, they called priority boarding and I was the second in the queue. After scanning the boarding pass of the lady in front of me, they announced to the queue that the business class bus had not yet reached. Another agent then came down the line asking passengers if they would like to take the bus which was waiting now or wait for the separate bus (which is the same type of bus, just to be used only by business class passengers).

Not surprisingly everyone I saw chose to get on the bus already at the door. The bus drove us to our A320 which was parked near the end of the airport.

Abu Dhabi (AUH) to Bangalore Kempegowda International (BLR). EY 286. STD 02:40 STA 08.15. All times local. 17-Jul-17. Airbus A320. Seat 2F.

I boarded via the front door and was greeted at the top of the stairs by one of the cabin crew and escorted to my seat.

Cabin and Seat

The A320 we were flying on had been refurbished with the new Etihad colors. The aircraft has four rows of business class seats in a standard 2-2 arrangement. I found the seat to be sufficiently wide with a lot of leg room. The seat also has a decent recline and foot rest. Upon taking my seat, I was quickly offered a drink. I took a lime and mint juice. I was also asked what drink I would like after takeoff.

The center armrest holds the fold out screen for the IFE which has a reasonable selection of content with Etihad’s older entertainment system. The system can be controlled with a remote stowed in the opposite armrest. Unfortunately being a fold out screen, it must be stowed for taxi, takeoff and landing.

The fold out IFE screen.

IFE remote.

After boarding completed, the pilot came over the PA and announced that due to congestion over Oman, pushback would be delayed. The aircraft began it’s push back 20 minutes after the scheduled departure time. After pushing back, the aircraft taxied towards the main taxiway and stopped.

We then waited on a cross taxiway for another 25 minutes while other larger aircraft taxied past and took off – it would have been interesting to know why our flight had low priority to take off was it just because we were in a smaller aircraft or are all flights to India lower priority or was the tower just waiting for a slot since we would have missed our original departure slot. We took off about 50 minutes after our scheduled departure time.

Food

Soon after takeoff the steward returned with my drink order and took down my dinner order and asked when I would like to dine. I requested him to bring my dinner after an hour which was done almost to the dot.

My first course was virtually identical to the flight from London, but missing the excellent bread. Again the mezze plater was average with nothing to write about.

The main course was a grilled chicken breast which had some flavour but was about as soft as a hockey puck.

The dessert was a chocolate cake with raspberry compote which was very good.

Overall, I found the meal service on Etihad to be strictly average, though their chocolate desserts are very good.

Through the dinner service and the entire flight I found the service to be excellent. The crew were attentive, quick and infectiously cheerful.

The rest of the flight proceeded uneventfully and we landed at Bangalore slightly after our scheduled arrival time.

Customer care response to pick up problem

I wrote to Etihad customer care as requested by the station manager in London, explaining the problem with the chauffeur pickup. After writing to them in July, I finally got a response at the end of September.

Their reply stated very unapologetically said that since I was a single passenger the airline policy is to only provide a sedan. So despite both the customer call center and London call center confirming that I would receive a mini van for the pickup – Etihad cannot guarantee that commitment. Because of which they are not responsible for the failure in the pickup.

Now I am ok with Etihad only providing a sedan to pick up a passenger, but I would have appreciated being told about that when I requested a bigger car. For the call center to confirm the mini van orally and then to be told that a van cannot be guaranteed is just bad customer service in my opinion. I think it just reflects the current state of Etihad that cost cutting is a higher priority than the passenger experience.

Overall

I enjoyed my flight on Etihad’s A320. The airline needs to look at an updated hard product for it’s business class with narrow body flat bed options on the rise, Etihad should be looking at one of these options sooner rather than later. While the food onboard was strictly average, the service was great.

I found overall experience on Etihad to be reasonably decent. While I am personally not a very a very big fan of the hard product on the A380, it is a very solid product and service across both the legs were good. However that being said Etihad’s cost cutting spree is beginning to show when it comes to the passenger experience. Etihad needs to be careful not to slip into the service level of the pack of the European carriers.

The airline definitely needs to improve it’s transit experience and customer care which are both sub standard.

Inflight review: Etihad Airways A320: Business Class: Abu Dhabi to Bangalore This is the third in a three part article of my trip from London to Bangalore.

[livehealthmedia]

A digital revolution in health care is speeding up

Telemedicine, predictive diagnostics, wearable sensors and a host of new apps will transform how people manage their health

WHEN someone goes into cardiac arrest, survival depends on how quickly the heart can be restarted. Enter Amazon’s Echo, a voice-driven computer that answers to the name of Alexa, which can recite life-saving instructions about cardiopulmonary resuscitation, a skill taught to it by the American Heart Association. Alexa is accumulating other health-care skills, too, including acting as a companion for the elderly and answering questions about children’s illnesses. In the near future she will probably help doctors with grubby hands to take notes and to request scans, as well as remind patients to take their pills.

Alexa is one manifestation of a drive to disrupt an industry that has so far largely failed to deliver on the potential of digital information. Health care is over-regulated and expensive to innovate in, and has a history of failing to implement ambitious IT projects. But the momentum towards a digital future is gathering pace. Investment into digital health care has soared (see chart).

One reason for that is the scale of potential cost-savings. Last year Americans spent an amount equivalent to about 18% of GDP on health care. That is an extreme, but other countries face rising cost pressures from health spending as populations age. Much of this expenditure is inefficient. Spending on administration varies sevenfold between rich countries. There are huge differences in the cost of medical procedures. In rich countries about one-fifth of spending on health care goes to waste, for example on wrong or unnecessary treatments. Eliminating a fraction of this sum is a huge opportunity.

Consumers seem readier to accept digital products than just a few years ago. The field includes mobile apps, telemedicine—health care provided using electronic communications—and predictive analytics (using statistical methods to sift data on outcomes for patients). Other areas are automated diagnoses and wearable sensors to measure things like blood pressure.

If there is to be a health-care revolution, it will create winners and losers. Andy Richards, an investor in digital health, argues that three groups are fighting a war for control of the “health-care value chain”.

One group comprises “traditional innovators”—pharmaceutical firms, hospitals and medical-technology companies such as GE Healthcare, Siemens, Medtronic and Philips. A second category is made up of “incumbent players”, which include health insurers, pharmacy-benefit managers (which buy drugs in bulk), and as single-payer health-care systems such as Britain’s NHS. The third group are the technology “insurgents”, including Google, Apple, Amazon and a host of hungry entrepreneurs that are creating apps, predictive-diagnostics systems and new devices. These firms may well profit most handsomely from the shift to digital.

The threat to the traditional innovators is that as medical records are digitised and new kinds of patient data arrive from genomic sequencing, sensors and even from social media, insurers and governments can get much better insight into which treatments work. These buyers are increasingly demanding “value-based” reimbursement—meaning that if a drug or device doesn’t function well, it will not be bought.

The big question is whether drug companies will be big losers, says Marc Sluijs, an adviser on investment in digital health. More data will not only identify those drugs that do not work. Digital health care will also give rise to new services that might involve taking no drugs at all.

Lunches eaten

Diabetes is an obvious problem for the pharma business in this regard, says Dan Mahony, a partner at Polar Capital, an investment firm. Since evidence shows that exercise gives diabetics better control of their disease (and helps most pre-diabetics not to get sick at all), there is an opening for new services. UnitedHealthcare, a big American insurer, for example, has a prevention programme that connects pre-diabetics with special coaches at gyms.

An app or a wearable device that persuades people to walk a certain distance every day would be far cheaper for insurers and governments to provide than years of visits to doctors, hospitals and drugs. Although Fitbits are frequently derided for ending up in the back of a drawer, people can be motivated to get off the sofa. Players of Pokémon Go have collectively walked nearly 9bn kilometres since the smartphone game was released last year.

That is the backdrop to a new firm called Onduo, a joint venture that Google’s health-care venture, Verily Life Sciences, and Sanofi, a French drug firm, set up last year. Onduo will start by developing ways to help diabetics make better decisions about their use of drugs and their lifestyle habits. Later on, Onduo wants to help those who are at risk of diabetes not to develop it. The startup is a good hedge for Sanofi, which faces a slowdown in sales of its blockbuster insulin medication, Lantus, which lost patent protection in 2015.

This kind of thinking does not come easily to drug firms. Switzerland’s Novartis is one of the few to have acknowledged that digital innovation will mean selling products based on patient outcomes. But if pharma firms do not design solutions that put the patient, rather than drug sales, at the centre of their strategy, they risk losing relevance, says Mr Sluijs.

Large hospitals, some of which count as both incumbents and traditional innovators, will also be affected. The rise of telemedicine, predictive analytics and earlier diagnoses of illnesses are expected to reduce admissions, particularly of the emergency kind that are most lucrative in commercial systems. The sickest patients can be targeted by specialist services, such as Evolution Health, a firm in Texas that cares for 2m of the most-ill patients across 15 states. It claims to be able to reduce the use of emergency rooms by a fifth, and inpatient stays in hospitals by two-fifths.

Rapid medical and diagnostic innovation will disrupt all businesses that rely heavily on physical facilities and staff. A mobile ultrasound scanner made by Philips, called Lumify, means that a far larger number of patients can be seen by their own doctors. As for data-based diagnostics, one potential example of its power to change business models is Guardant Health, a startup that is analysing large quantities of medical data in order to develop a way of diagnosing cancer from blood tests. If the firm can devise an early test for breast cancer, demand for mammograms and the machines that take them would fall, along with the need for expensive drugs and spells in hospital.

From ER to AI

There is also good news for hospitals, however. Increasingly, machine-learning programs are able to make diagnoses from scans and from test results. An intriguing recent project has been to stream and analyse live health data and deliver alerts on an app that is carried around by doctors and nurses at the Royal Free Hospital in London. The app, which is the work of DeepMind, a British artificial-intelligence (AI) research firm owned by Google, identifies the patients at greatest risk of a sudden and fatal loss of kidney function. The Royal Free says that the app is already saving nurses’ time.

Naturally enough, the health-care entrepreneurs have the boldest visions. The point of care will move rapidly into the home, they say. People will monitor their heart conditions, detect concussions, monitor the progress of diseases and check up on moles or ear infections using apps, mobile phones and sensors. Last year the FDA approved 36 connected health apps and devices. A new app, called Natural Cycles, was recently approved in Europe for use as a contraceptive. Its failure rate for typical use was equivalent to that of popular contraceptive pills. A smartphone may eventually be able to predict the onset of Alzheimer’s, Parkinson’s or even the menopause (if the information is wanted).

In emerging economies, where regulations on health data are less onerous and where people often already expect to pay to see a doctor, there is faster growth and innovation. China, which is building 400 hospitals a year, saw its two largest VC investments in digital health care last year. One went into a Chinese medical-service app, Ping An Good Doctor, which raised $500m; a video-consultations app called Chunyu Yisheng raised $183m. India is another innovator. 

To take one example, LiveHealth, based in Pune, is an app that lets patients assemble all their health records in one place, see test results and communicate with doctors.

In the short term, the greatest disruption will come from a growing array of apps in many countries around the world that give consumers direct access to qualified GPS on their mobile phones. Overall, telemedicine is expected to grow rapidly. In America, GPs will conduct 5.4m video consultations a year by 2020, says IHS Markit, a research firm. Britain’s NHS is testing a medical AI from a London-based startup called Babylon which can field patients’ questions about their health. A paid service called Push Doctor offers an online appointment almost immediately for £20 ($24). The firm maximises the efficiency of its doctors by reducing the time they spend on administrative duties. They spend 93% of their time with patients compared with only 61% in Britain’s public sector. Babylon reckons that 85% of consultations do not need to be in person.

In the longer term, the biggest upheaval may come from the large technology firms. Amazon and Google are not the only giants to be stalking health care. Apple has expressed a strong interest in it, though it is taking time to decide exactly what it wants to do. For several years it has provided a way of bringing together health data on its iPhone, and tools for health researchers to build apps. As personal-health records accumulate on its platform, from sensors such as Fitbits to medical-grade devices, it will encourage more app development.

An app using data from an iPhone or another smartphone might be able to warn users that a sedentary lifestyle will exacerbate a heart condition or that, based on social-media patterns, they are at risk of depression, for example. Apple and other tech firms may also be able to help patients take greater control of their existing health records. For now medical records mostly remain under the guard of those who provided the care, but this is expected to change. If patients do gain proper access to their own data, Apple is in a particularly strong position. Its platform is locked and fairly secure, and the apps that run on it are all screened by the firm.

None of this will materialise quickly. Regulated health-care systems will take time to deal with concerns over accuracy, security and privacy. In Britain the Royal Free is already under scrutiny over how it shared its patients’ data. That suggests a broader worry: that technology companies are too cavalier with their users’ data. Such firms typically use long agreements on data rights that are hard for individuals to understand. The medical world places importance on informed consent, so a clash of cultures seems unavoidable.

Yet enormous change looks inevitable. Investors hope for billion-dollar health-tech “unicorns”. Payers eye equally sizeable savings. Amid such talk it is worth remembering that the biggest winners from digital health care will be the patients who receive better treatment, and those who avoid becoming patients at all.

The Economist- The wonder drug

[iscanbreast]

Breast Abnormalities Screening Device

Early detection of breast abnormalities is crucial in preventing and managing breast cancer. Thanks to advancements in technology, devices like the Breast Abnormalities Screening Device by iScanBreast have made it easier for women to monitor their breast health at home. This innovative solution empowers individuals to take control of their health with reliable and user-friendly tools.

The Need for Early Detection

Breast cancer is one of the leading causes of cancer-related deaths among women. Detecting abnormalities at an early stage significantly increases the chances of successful treatment. The Breast Cancer Early Screening Device by iScanBreast provides an accessible and effective way to identify potential issues before they escalate. By incorporating such devices into regular health routines, women can proactively safeguard their well-being.

What is the iScanBreast - Breast Self-Examination Device?

The iScanBreast - Breast Self-Examination Device is designed to assist women in performing thorough and accurate self-examinations. Its cutting-edge technology ensures reliable results while being simple enough for everyday use. This device is an essential tool for anyone looking to stay informed about their breast health.

Features of the Breast Abnormalities Screening Device

Advanced Technology: The device uses state-of-the-art sensors to detect potential abnormalities with high precision.

Ease of Use: Designed for home use, the device is intuitive and requires no professional expertise.

Non-Invasive: A completely safe and pain-free way to monitor breast health.

Compact Design: Portable and lightweight, making it convenient for regular use.

Affordable: A cost-effective alternative to frequent clinical screenings.

Benefits of Using a Breast Cancer Early Screening Device

Early Intervention: Detecting issues early can lead to timely medical action, increasing treatment success rates.

Convenience: Self-examinations at home eliminate the need for frequent clinic visits.

Empowerment: Women can take an active role in monitoring their health with confidence.

Peace of Mind: Regular use provides reassurance and reduces anxiety about breast health.

Why Choose the iScanBreast Device?

The iScanBreast - Breast Self-Examination Device stands out for its innovation, reliability, and ease of use. With a mission to make breast health accessible to all, iScanBreast has created a product that combines cutting-edge technology with practical functionality. This device ensures that every woman has the tools needed to stay proactive about her health.

How to Use the iScanBreast Device

Prepare: Follow the device’s instructions for proper setup.

Scan: Use the device to examine each breast thoroughly, following the recommended technique.

Review: Check the results and consult a healthcare professional if any abnormalities are detected.

Conclusion

The Breast Abnormalities Screening Device by iScanBreast is a groundbreaking tool for proactive breast health management. By offering a reliable and user-friendly solution, it empowers women to take charge of their well-being. Visit www.iscanbreast.com to learn more about this innovative device and take the first step towards early detection and peace of mind.

[iscanbreast]

Empowering Women: The iScanBreast Self-Examination Device

Early detection is key to breast cancer survival. With the iScanBreast, you can take charge of your breast health and conduct regular self-examinations from the comfort of your home.

What is iScanBreast?

iScanBreast is a revolutionary non-diagnostic device designed to help women understand their breast health. It uses advanced technology to scan your breasts and provide real-time feedback. By using iScanBreast regularly, you can identify any changes in your breast tissue early on, enabling timely medical intervention.

How Does iScanBreast Work?

Easy to Use: The device is simple to operate, and you can use it independently.

Non-Invasive: The scanning process is painless and non-invasive.

Real-Time Feedback: Get immediate visual feedback on your breast health.

Discreet and Portable: The compact design allows for easy storage and use anywhere.

Why is Self-Examination Important?

Regular self-breast exams are crucial for early detection of breast cancer. Early detection significantly improves the chances of successful treatment. With iScanBreast, you can perform self-exams more frequently and confidently.

Benefits of Using iScanBreast:

Early Detection: Identify potential abnormalities early on.

Peace of Mind: Regular self-exams can reduce anxiety and provide reassurance.

Empowerment: Take control of your breast health and become an active participant in your healthcare.

Join the Movement

By using iScanBreast, you're not just taking care of your health; you're empowering yourself and other women. Let's work together to raise awareness about breast cancer and promote early detection.

[healthcare-market]

Microarray Scanners Market Projected to Gain Significant Value by 2030

Microarray Scanners Market: Introduction

According to the report, the global microarray scanners market was valued at US$ 700 Mn in 2019 and is projected to expand at a CAGR of ~7% from 2020 to 2030. Emergence and adoption of technologically advanced instruments in life science, rise in demand for preventive healthcare, well-established healthcare facilities, rapidly increasing geriatric population, and high per capita healthcare expenditure are anticipated to drive the global microarray scanners market from 2020 to 2030. North America is expected to account for significant share of the global microarray scanners market during the forecast period. The growth of the market in the region can be attributed to well-established healthcare and life sciences industries, early adoption of technologically advanced products, high awareness about various infectious as well as chronic diseases, and high per capita healthcare expenditure.

The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031, due to the expansion of the healthcare sector in countries such as China, Japan, and India. Moreover, increase in drug research & development in countries such as Japan, India, and China is projected to propel the market in the region during the forecast period.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45156

Rise in Awareness, Acceptance of Personalized Medicine, Companion Diagnostics to Propel Market

The demand for personalized medicine is increasing at a significant rate. Personalized medicine is defined as a practice of customization of an individual’s requirement using genetic profiling. Inclination toward personalized medicines can be ascribed to the efficiency and target-specific nature of medicines with better patient outcomes. According to a study published in the World Academy of Sciences Journal 2019, protein microarrays are paving the way for personalized medicine. Personalized medicine aims to stratify patients as per type of the disease, treatment response, evaluated prognosis, and its risk factors. Microarrays are being tried to develop personalized medicine for various disease types, including cell renal carcinoma, breast & ovarian cancers, and pulmonary diseases.

Additionally, targeted therapies have minimal or no side effects compared to conventional therapies. Significant sophistication in genomics research and biomarkers has encouraged several pharmaceutical companies to shift focus toward the development of novel targeted therapies. This accelerated adoption of companion diagnostics has led to a gradual decline of the traditional model.

Request for Analysis of COVID19 Impact on Microarray Scanners Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=45156

Fluorescence Microarray Scanners to Dominate Market

In terms of product type, the global microarray scanners market has been classified into fluorescence microarray scanners, charge-coupled devices microarray scanners, colorimetric microarray scanners, and others. The fluorescence microarray scanners segment is expected to dominate the global microarray scanners market by 2030. Fluorescence microarray scanners are highly common and widely utilized microarray detection devices. This is expected to drive the segment during the forecast period.

Gene Expression to be Highly Attractive Application

Based on application, the global microarray scanners market has been categorized into gene expression, drug discovery, and others. The gene expression segment is projected to dominate the global microarray scanners market during the forecast period. Application of gene expression for profiling for diseases, such as cardiovascular diseases including endothelial dysfunction, myocardial infarction, heart failure, cardiac hypertrophy, and atherosclerosis, is expected to drive the segment during the forecast period.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=45156

Diagnostic Laboratories to Account for Major Market Share

In terms of end user, the global microarray scanners market has been divided into hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, and academic & research institutes. The diagnostic laboratories segment is anticipated to account for a significant share of the global microarray scanners market by 2030. Diagnostic laboratories is expected to be a highly lucrative segment due to availability of facilities in diagnostics labs.

Buy now Microarray Scanners Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=45156&ltype=S

Competition Landscape in Microarray Scanners Market

The report provides profiles of leading players operating in the global microarray scanners market. These include Thermo Fisher Scientific, Agilent Technologies, Illumina, Inc., PerkinElmer Inc., F. Hoffmann-La Roche Ltd., GE Healthcare (General Electric Company), Molecular Devices, LLC (Danaher Corporation), Innopsys Inc., and Berthold Technologies GmbH & Co. KG.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/availability-of-sizeable-number-of-lightweight-devices-especially-for-use-by-the-elderly-substantiates-impressive-demand-in-oxygen-conserving-devices-market-continued-rd-to-spur-growth-says-tmr-301307841.html

https://www.prnewswire.com/news-releases/rising-number-of-osteoporosis-cases-boosts-demand-avenues-in-viscosupplementation-market-says-transparency-market-research-301312591.html

https://www.prnewswire.com/news-releases/rising-diabetic-patients-pool-prompts-high-demand-for-smart-insulin-pens-market-estimated-to-be-valued-at-us-70-4-mn-by-2027-end-tmr-301316368.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/